|
 Chief Executive Pascal Soriot said on Thursday the British company
had no plans for second-half increases, matching similar commitments
from Pfizer, Novartis, Roche and Merck.
"There is a clear commitment in the company to not increase prices
in the second half of the year," he told reporters.
In the first half, AstraZeneca raised U.S. list prices by a "modest"
1 to 3 percent, while net prices after rebates are actually falling,
he said.
Trump made lowering prescription drug prices a top 2016 presidential
campaign issue and has criticized drugmakers for raising prices,
saying in a tweet this month that they "should be ashamed".
[to top of second column] |
The real impact of corporate declarations on second-half pricing
remains open to debate, however, with analysts noting that freezes
this year could still leave leeway for increases in 2019.
(Reporting by Ben Hirschler; editing by Jason Neely)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
